Pathkey.AI (ASX:PKY) AI-powered clinical trial analytics platform, TrialKey, analyzed 42 clinical trials in peptide-based therapies for type-2 diabetes and obesity in a proof-of-concept study, identifying key molecular and patient drivers of trial success, according to a Thursday Australian bourse filing.
It highlighted features such as peptide length, molecular weight, receptor binding, and patient comorbidities as critical drivers of trial success.
The firm is incorporating drug-level features in TrialKey, such as molecular structure and pharmacokinetic properties, alongside traditional trial variables, allowing for AI-powered drug discovery and repurposing.
Its shares jumped 17% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.